WHAT IS CLAIMED IS:

1. A process for forming a pharmaceutical composition comprising:

(a) preparing core particles comprising an active agent of topiramate;

(b) drying the core particles from step (a) to form dried core particles;

(c) coating the dried core particles from step (b) with a taste masking mixture to form coated particles; and

(d) drying the coated particles from step (c) to form the pharmaceutical composition wherein the amount of taste masking mixture ranges from about 7% by weight to about 15% by weight of the pharmaceutical composition.

2. The process of Claim 1, wherein the core particles comprise the active agent of topiramate and at least one excipient.

3. The process of Claim 2, wherein the core particles comprise the active agent of topiramate, a binder and a diluent wherein the diluent is sugar spheres.

4. The process of Claim 3, wherein the taste masking mixture comprises about 9 to about 13% by weight of the pharmaceutical composition.

5. The process of Claim 4, wherein the dried core particles of step (b) are sized to between about 0.100 mm and about 2.5 mm prior to coating with the taste masking mixture.

6. The process of Claim 5, wherein the coated particles from step (d) are sized to between about 0.100 mm and about 2.5 mm.

7. The process of Claim 6, wherein the core particles are prepared by spraying a suspension of topiramate and the binder in a solvent onto the sugar spheres.

8. The process of Claim 7, wherein the binder is selected from povidone, HPMC, acacia gum, sugar, molasses, sodium alginate, panwar gum, starch, pregelatinized starch, carboxymethylcellulose, ethylcellulose or methylcellulose.

9. The process of Claim 8, wherein the binder is povidone.

10. The process of Claim 8, wherein the taste masking mixture comprises a taste masking agent selected from cellulose acetate, cellulose acetate buytrate, methylcellulose, ethylcellulose or a Eudragit; and a disintegrant selected from povidone, methylcellulose, starch, sodium starch glycolate, pregelatinized starch, cellulose, carboxymethylcellulose, croscarmellose sodium, magnesium aluminate silicate, alginic acid or guar gum.

11. The process of Claim 10, wherein the taste masking mixture comprises cellulose acetate and povidone.

12. The process of Claim 11, further comprising encapsulating the coated bead.

13. A pharmaceutical composition made by the process of Claim 1.

14. A pharmaceutical composition comprising

(a) core particles containing an active agent of topiramate, wherein the core particles have an initial particle size between about 0.100 mm and 2.5 mm; and

(b) a taste mask coating, wherein the taste mask coating comprises between about 7% by weight and about 15% by weight of the pharmaceutical composition and wherein the coated particles of the pharmaceutical composition have a final particle size of about 0.100 mm to about 2.5 mm.

15. The pharmaceutical composition of Claim 14, wherein the core particles comprise the active agent of topiramate and at least one excipient.

16. The pharmaceutical composition of Claim 15, wherein the core particles comprise the active agent of topiramate, a binder and a diluent wherein the diluent is sugar spheres.

17. The pharmaceutical composition of Claim 16, wherein the taste mask coating comprises between about 9% by weight and about 13% by weight of the pharmaceutical composition.

18. The pharmaceutical composition of Claim 17, wherein the taste mask coating comprises about 11% by weight of the pharmaceutical composition.

19. The pharmaceutical composition of Claim 18, wherein the core particles have an initial particle size between about 0.5 mm and 1.5 mm and the coated particles of the pharmaceutical composition have a final particle size between about 0.5 mm and 1.5 mm.

20. The pharmaceutical composition of Claim 19, wherein the core particles have an initial particle size between about 0.710 mm and 1.18 mm and the coated particles of the pharmaceutical composition have a final particle size between about 0.850 mm and 1.18 mm.

21. The pharmaceutical composition of Claim 20, wherein the binder is selected from povidone, HPMC, sodium alginate, panwar gum, acacia gum, gelatin, sugar, molasses, starch, pregelatinized starch, methycellulose, ethylcellulose or caroboxymethylcellulose; and the taste mask coating comprises a taste masking agent and a disintegrant, wherein the taste masking agent is selected from cellulose acetate, methylcellulose, ethylcellulose, a Eudragit or cellulose acetate butyrate; and the disintegrant is selected from povidone, cellulose, carboxymethylcellulose, croscarmellose sodium, magnesium

aluminate silicate, starch, sodium starch glycolate, pregelatinized starch, alginic acid or guar gum.

22. The pharmaceutical composition of Claim 21, wherein the binder is povidone, the taste masking agent is cellulose acetate and the disintegrant is povidone.

23. The pharmaceutical composition of Claim 22, wherein the coated particles of the pharmaceutical composition are encapsulated.

24. A pharmaceutical composition comprising about 85 to about 93% by weight core beads, and about 7 to about 15% by weight of a coating; wherein the core beads comprise about 18 to about 21% by weight of topiramate, about 8 to about 11% by weight of povidone, and about 58 to about 61% by weight of sugar spheres; and the coating comprises about 6 to about 9% by weight of cellulose acetate, and about 2 to about 5% by weight of povidone.

25. The pharmaceutical composition of Claim 24, comprising about 89% by weight of core beads and about 11% by weight coating, wherein the core beads comprise about 19.8% by weight topiramate, about 9.9% by weight povidone, and about 59.3% by weight sugar spheres; and the coating comprises about 7.2% by weight cellulose acetate and about 3.8% by weight povidone.

26. A method of treating convulsions in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of the pharmaceutical composition of Claims 14.

27. A method of treating epilepsy in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of the pharmaceutical composition of Claims 14.